Novozymes' bioenergy unit exceeds consensus amid wide H1 setback

Novozymes' bioenergy unit was the company's only division to perform better than expected. Altogether, the group had to swallow a negative organic growth of 3 percent for the first half of 2019.
Photo: Keld Navntoft / Ritzau Scanpix
Photo: Keld Navntoft / Ritzau Scanpix
BY VICTOR EMIL KRISTENSEN

Danish enzyme producer Novozymes published an expectedly disappointing biannual financial statement Thursday morning and thereby continues into a 2019 that Chief Executive Peder Holk Nielsen would likely prefer to forget.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    On June 1, Senvion's former CFO Manav Sharma started as US country manager for Nordex. Soon he will have a new factory at his disposal. | Foto: Senvion

    Nordex restarts production in the US

    For subscribers

    Further reading